Häberle Lothar, Hein Alexander, Rübner Matthias, Schneider Michael, Ekici Arif B, Gass Paul, Hartmann Arndt, Schulz-Wendtland Rüdiger, Beckmann Matthias W, Lo Wing-Yee, Schroth Werner, Brauch Hiltrud, Fasching Peter A, Wunderle Marius
Department of Gynecology and Obstetrics, Erlangen University Hospital, University Breast Center for Franconia, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Biostatistics Unit, Department of Gynecology and Obstetrics, Erlangen University Hospital, Erlangen, Germany.
Geburtshilfe Frauenheilkd. 2017 Jun;77(6):667-678. doi: 10.1055/s-0043-111602. Epub 2017 Jun 28.
Studies of triple-negative breast cancer have recently been extending the inclusion criteria and incorporating additional molecular markers into the selection criteria, opening up scope for targeted therapies. The screening phases required for studies of this type are often prolonged, since the process of determining the molecular subtype and carrying out additional biomarker assessment is time-consuming. Parameters such as germline genotypes capable of predicting the molecular subtype before it becomes available from pathology might be helpful for treatment planning and optimizing the timing and cost of screening phases. This appears to be feasible, as rapid and low-cost genotyping methods are becoming increasingly available. The aim of this study was to identify single nucleotide polymorphisms (SNPs) for breast cancer risk capable of predicting triple negativity, in addition to clinical predictors, in breast cancer patients.
This cross-sectional observational study included 1271 women with invasive breast cancer who were treated at a university hospital. A total of 76 validated breast cancer risk SNPs were successfully genotyped. Univariate associations between each SNP and triple negativity were explored using logistic regression analyses. Several variable selection and regression techniques were applied to identify a set of SNPs that together improve the prediction of triple negativity in addition to the clinical predictors of age at diagnosis and body mass index (BMI). The most accurate prediction method was determined by cross-validation.
The SNP rs10069690 was the only significant SNP (corrected p = 0.02) after correction of p values for multiple testing in the univariate analyses. This SNP and three additional SNPs from the genes and were selected for prediction of triple negativity. The addition of these SNPs to clinical predictors increased the cross-validated area under the curve (AUC) from 0.618 to 0.625. Age at diagnosis was the strongest predictor, stronger than any genetic characteristics.
Prediction of triple-negative breast cancer can be improved if SNPs associated with breast cancer risk are added to a prediction rule based on age at diagnosis and BMI. This finding could be used for prescreening purposes in complex molecular therapy studies for triple-negative breast cancer.
三阴性乳腺癌的研究最近一直在扩大纳入标准,并将更多分子标志物纳入选择标准,为靶向治疗开辟了空间。这类研究所需的筛查阶段往往会延长,因为确定分子亚型和进行额外生物标志物评估的过程很耗时。能够在病理结果得出之前预测分子亚型的种系基因型等参数,可能有助于治疗规划以及优化筛查阶段的时间和成本。随着快速且低成本的基因分型方法越来越多,这似乎是可行的。本研究的目的是在乳腺癌患者中,除了临床预测指标外,识别能够预测三阴性的乳腺癌风险单核苷酸多态性(SNP)。
这项横断面观察性研究纳入了在一家大学医院接受治疗的1271例浸润性乳腺癌女性患者。总共成功对76个经过验证的乳腺癌风险SNP进行了基因分型。使用逻辑回归分析探索每个SNP与三阴性之间的单变量关联。应用了几种变量选择和回归技术,以识别一组除了诊断年龄和体重指数(BMI)这些临床预测指标外,还能共同改善三阴性预测的SNP。通过交叉验证确定最准确的预测方法。
在单变量分析中对多重检验的p值进行校正后,SNP rs10069690是唯一显著的SNP(校正p = 0.02)。选择该SNP以及另外三个来自相关基因的SNP用于预测三阴性。将这些SNP添加到临床预测指标中,交叉验证的曲线下面积(AUC)从0.618增加到0.625。诊断年龄是最强的预测指标,比任何遗传特征都更强。
如果将与乳腺癌风险相关的SNP添加到基于诊断年龄和BMI的预测规则中,三阴性乳腺癌的预测可以得到改善。这一发现可用于三阴性乳腺癌复杂分子治疗研究的预筛查目的。